Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain
RecruitingNot applicableNCT06360965
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic Pelvic Pain is one of the common gynecological symptoms, characterized by persistent and non periodic pain in the pelvic cavity and surrounding tissues. It is often seen as a sequelae of pelvic inflammatory diseases caused by the failure to receive timely and correct treatment. This study compares the effectiveness of warm meridians and relieve pain plaster in relieving the sequelae of pelvic inflammatory disease and chronic pelvic pain symptoms, and evaluates the safety of improved patches and traditional patches, further promoting it to community grassroots hospitals.
Study details
- Official title
- A Randomized Controlled Trial on the Clinical Efficacy and Safety of Warm Meridians and Relieve Pain Plaster in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain (Cold Dampness Stasis Type).
- Conditions
- Pelvic Inflammatory Disease
- Chronic Pelvic Pain Syndrome
- Interventions
- Drug: Improved warm meridians and relieve pain plaster
- Drug: Traditional warm meridians and relieve pain plaster
- Drug: Placebo plaster
- Sponsor
- Beijing Hospital of Integrated Traditional Chinese and Western Medicine
- Start date
- 2024-01-01
- Primary completion
- 2026-03-31
- Sex
- Female
- Age range
- from 18 Years to 50 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Meets the diagnostic criteria of traditional Chinese and Western medicine for sequelae of pelvic inflammatory disease and chronic pelvic pain; 2. Transvaginal ultrasound examination shows thickening of the fallopian tube wall and fluid accumulation in the lumen, which may be accompanied by pelvic free fluid or fallopian tube ovarian masses; 3. The age range is 18-50 years old, married or with a history of sexual activity; 4. Those with a menstrual cycle of 21-35 days; 5. 4 points ≤ Pain Visual Analog Scale (VAS) \< 7 points; 6. Those who have signed an informed consent form and are willing to receive treatment. Exclusion Criteria: 1. Female patients who have fertility requirements during pregnancy, lactation, or in the short term; 2. Patients with gynecological diseases such as organic lesions of the reproductive system or gynecological acute abdomen; 3. Chronic pelvic pain caused by gynecological tumors, endometriosis, pelvic congestion syndrome, uterine fibroids, tuberculous pelvic inflammatory disease, and other diseases confirmed through examination; 4. Those with severe diseases such as cardiovascular, cerebrovascular, liver and kidney function, and digestive system; 5. Individuals with mental abnormalities and psychological disorders; 6. Individuals with allergic constitution or known allergies to the drugs and their components used in this experiment; 7. Patients currently participating in clinical trials of other drugs; 8. Other methods of treatment have already been or are currently being carried out, which may affect the indicators observed in this study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06360965